一项分两部分的单次和多次递增剂量试验,研究 LBT-3627 在健康受试者和帕金森病受试者中的安全性、耐受性、药代动力学和药效学。
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
研究概览
详细说明
Evaluate the safety and tolerability of LBT-3627 in both a single and multiple ascending dose study.
Phase Ia will explore safety and tolerability first in healthy volunteers then followed by Parkinson's patients after a single dose. Dose levels will escalate per cohort.
Phase Ib will explore safety and tolerability in Parkinson's patients after multiple doses. Dose levels will escalate per cohort.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Kelly Bertram, MD
- 电话号码:+61 0487 531 448
- 邮箱:k.bertram@alfred.org.au
学习地点
-
-
Victoria
-
Melbourne、Victoria、澳大利亚、3004
- 招聘中
- Alfred Hospital
-
接触:
- Beth Sutherland
- 电话号码:+61 0487 531 448
- 邮箱:B.Sutherland@alfred.org.au
-
Melbourne、Victoria、澳大利亚、3168
- 招聘中
- Monash Medical Center
-
接触:
- May Ho
- 电话号码:+61 03 9594 3051
- 邮箱:wing.ho@monashhealth.org
-
Melbourne、Victoria、澳大利亚
- 主动,不招人
- Nucleus Networks
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Both cohorts (Healthy Volunteers and Parkinson's Disease)
Key inclusion criteria
- Male or female, 30-89 years inclusive at screening
- BMI 18-32 kg/m²
- Vital signs, ECG (QTcF <450 ms male / <470 ms female), and safety labs without clinically significant abnormality; no orthostatic hypotension
- Women of non-childbearing potential, or using highly effective contraception per protocol
Key exclusion criteria
- Immunomodulators / steroids - HV: any (incl. OTC) within 90 days; PD: systemic within 60 days and topical/nasal-inhaled OTC within 7 days (both waivable only with Sponsor approval)
- Vaccine within 60 days (HV) / 45 days (PD) of first dose
- CoQ10 within 5 days
- Inadequate renal function (CrCl ≤ 60 mL/min; ≤ 79 if HV under 40), or LFTs / bilirubin > 1.5× ULN
- Clinically significant cardiovascular, hepatic, renal, neurological, or psychiatric disease
- Active infection requiring systemic anti-infectives within 14 days; positive HBV/HCV/HIV serology
Parkinson's Disease participants - additional key inclusion criteria
- PD diagnosis by a neurologist/geriatrician, 6 months to < 11 years before first dose, per MDS clinical diagnostic criteria
- Hoehn & Yahr stage 1-3
- If on levodopa: stable ≥ 2 months and able to withhold ≥ 12 hours (overnight) around dosing/assessments; if not, remain treatment-naïve through end of study
Parkinson's Disease participants - additional key exclusion criteria
- Prior PD brain surgery, focused ultrasound, or neuromodulation; no anti-amyloid/anti-tau biologics
- Antibiotics within 30 days; OTC pre/probiotics; ≥ 3 unexplained falls in 12 months
Note: Additional protocol-defined criteria apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Healthy Volunteers - SAD
Single dose of LBT-3627 administered to healthy volunteers |
Synthetic peptide Vehicle |
|
实验性的:Parkinson's disease patients - SAD
Single dose of LBT-3627 administered to Parkinson's disease patients |
Synthetic peptide Vehicle |
|
实验性的:Parkinson's disease patients - MAD
Multiple doses of LBT-3627 administered to Parkinson's disease patients |
Synthetic peptide Vehicle |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
不良事件的发生率、性质和严重程度[安全性和耐受性]
大体时间:治疗当天至随访期结束(1、2 或 4 周)
|
治疗当天至随访期结束(1、2 或 4 周)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum Plasma Concentration [Cmax]
大体时间:Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
The peak plasma concentration of a drug after administration. |
Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
|
Elimination half life [T1/2]
大体时间:Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
The time required for the concentration of the drug to reach half of its original value. |
Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
|
Time to reach Cmax [Tmax]
大体时间:Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
Time required to reach Cmax. |
Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
|
Volume of Distribution [Vd]
大体时间:Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
The apparent volume in which a drug is distributed (i.e., the parameter relating drug concentration in plasma to drug amount in the body). |
Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
|
Concentration [C]
大体时间:Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
Amount of drug in a given volume of plasma |
Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
|
Area under the curve [AUC]
大体时间:Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
The integral of the concentration-time curve (after a single dose or in steady state). |
Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
|
Clearance [CL]
大体时间:Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
The volume of plasma cleared of the drug per unit time. |
Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
|
Bioavailability [f]
大体时间:Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
The systemically available fraction of a drug. |
Day of treatment to end of follow-up period (1, 2 or 4 weeks)
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.